CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the COVID-19 pandemic ...

U.S. equities declined in Tuesday’s midday trade after surging during the morning session, after President Donald Trump ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Archer Daniels Midland logged lower profit and revenue in the second quarter, hurt by what Chief Executive Juan Luciano called a challenging environment. Yum Brands logged higher profit and sales in ...

Bourla, who took over as CEO in 2019, has declined to say how long he intends to remain in his role at Pfizer. Developing a ...

Pfizer (PFE) increased its 2025 profit outlook by 10 cents a share to a range of $2.90 to $3.10 a share, citing continued cost cuts, a lower tax rate and "confidence" that strength seen in the first ...

Many viruses circulate seasonally, picking up as the weather cools in the fall and winter. So it’s true that fewer people get ...

Pfizer posted second-quarter financial results Tuesday that beat market expectations. The company also raised its full-year earnings guidance from more conservative benchmarks set earlier this ...

US stocks open higher as investors bet on a rate cut and digest earnings. Trump threatens more tariffs and talks Fed chair candidates in interview.

Trump’s drug and chip tariffs could reshape supply chains before they launch. Here’s how escalating rates and hidden costs ...